Literature DB >> 12969186

Slow viral dynamics of hepatitis C virus genotype 4.

P Halfon1, A U Neumann, M Bourlière, A Rieu, S Chadapaud, H Khiri, D Ouzan, P Cacoub.   

Abstract

Patients infected with hepatitis C virus genotype 4 (HCV-4) respond to interferon alpha (IFN) as poorly as those infected with genotype 1. However, there is no information on the viral dynamics of HCV-4. Interferon-ribavirin treatment was administered to untreated patients infected with HCV-4. Viral load was assessed with Versant 3.0. Viral dynamics parameters were estimated based on the bi-phasic model for HCV during IFN treatment. Viral kinetics of HCV-4 follow a bi-phasic decline pattern also. The mean effectiveness of IFN in blocking production of HCV-4 was a decline of 77.8% during the first day of treatment. The half-life of free virions was estimated at 3.5 h and that of infected cells from 1.9 to over 70 days. The viral dynamics parameters of HCV-4 appear similar to those of HCV-1 and slower than those of HCV-2. HCV-4 infected patients should be grouped with those with HCV-1 when therapeutic schemes are considered in relation to genotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969186     DOI: 10.1046/j.1365-2893.2003.00433.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  8 in total

1.  Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.

Authors:  S M Kamal; A A El Tawil; T Nakano; Q He; J Rasenack; S A Hakam; W A Saleh; A Ismail; A A Aziz; M Ali Madwar
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

2.  Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.

Authors:  Jose-Eymard Medeiros-Filho; Isabel-Maria-Vicente-Guedes de Carvalho Mello; Joao-Renato-Rebello Pinho; Avidan-U Neumann; Fernanda de Mello Malta; Luiz-Caetano da Silva; Flair-Jose Carrilho
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

3.  HCV antibody response and genotype distribution in different areas and races of China.

Authors:  Leili Jia; Jiyun Yu; Jinliang Yang; Hongbin Song; Xuelin Liu; Yong Wang; Yuanyong Xu; Chuanfu Zhang; Yanwei Zhong; Qiao Li
Journal:  Int J Biol Sci       Date:  2009-06-13       Impact factor: 6.580

4.  Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0.

Authors:  Jannick Verbeeck; Mark J Stanley; Jen Shieh; Linda Celis; Els Huyck; Elke Wollants; Judy Morimoto; Alice Farrior; Erwin Sablon; Margaret Jankowski-Hennig; Carl Schaper; Pamela Johnson; Marc Van Ranst; Marianne Van Brussel
Journal:  J Clin Microbiol       Date:  2008-04-09       Impact factor: 5.948

5.  IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1.

Authors:  Marine Karchava; Lali Sharvadze; Nikoloz Chkhartishvili; Kenrad Nelson; Nino Gochitashivli; Lana Gatserelia; Natia Dvali; Ekaterine Dolmazashvili; Lela Dzigua; Nino Badridze; Maia Zhamutashvili; Tengiz Tsertsvadze
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-07       Impact factor: 2.566

6.  Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients.

Authors:  Denis Ouzan; Hacène Khiri; Guillaume Pénaranda; Hélène Joly; Philippe Halfon
Journal:  Comp Hepatol       Date:  2005-12-21

Review 7.  IFN-λ: A New Class of Interferon with Distinct Functions-Implications for Hepatitis C Virus Research.

Authors:  Bing Liu; Ian McGilvray; Limin Chen
Journal:  Gastroenterol Res Pract       Date:  2015-05-20       Impact factor: 2.260

8.  Hepatitis C virus prevalence and genetic diversity among pregnant women in Gabon, central Africa.

Authors:  Guy-Roger Ndong-Atome; Maria Makuwa; Richard Njouom; Michel Branger; Francoise Brun-Vézinet; Antoine Mahé; Dominique Rousset; Mirdad Kazanji
Journal:  BMC Infect Dis       Date:  2008-06-17       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.